Patent Trolls Invade MedTech | MDDI Online
While patent trolls have plagued the technology sector, the medical device industry has largely been spared—until now.
By David J. Dykeman and Michael A. Cohen
If Paul Revere were riding through the streets of Boston today, he would likely be shouting, “The patent trolls are coming! The patent trolls are coming!”
David J. Dykeman is co-chair of the Global Life Sciences & Medical Technology Group of international law firm Greenberg Traurig LLP. A registered patent attorney with more than 17 years of experience in patents, intellectual property, and licensing, Dykeman's practice focuses on securing strategic worldwide intellectual property protection and related business strategy for high-tech clients, with particular expertise in medical devices, life sciences, biotechnology, and healthcare IT. He is also a member of MD+DI's editorial advisory board. Dykeman can be reached at 617/310-6009 or [email protected].
Patent Trolls Invade MedTech | MDDI Online
While patent trolls have plagued the technology sector, the medical device industry has largely been spared—until now.
By David J. Dykeman and Michael A. Cohen
If Paul Revere were riding through the streets of Boston today, he would likely be shouting, “The patent trolls are coming! The patent trolls are coming!”
David J. Dykeman is co-chair of the Global Life Sciences & Medical Technology Group of international law firm Greenberg Trau
rig LLP. A registered patent attorney with more than 17 years of experience in patents, intellectual property, and licensing, Dykeman's practice focuses on securing strategic worldwide intellectual property protection and related business strategy for high-tech clients, with particular expertise in medical devices, life sciences, biotechnology, and healthcare IT. He is also a member of MD+DI's editorial advisory board. Dykeman can be reached at 617/310-6009 or [email protected].